Literature DB >> 24072508

Cerebral microbleeds and the risk of mortality in the general population.

Saloua Akoudad1, Mohammad Arfan Ikram, Peter Jan Koudstaal, Albert Hofman, Aad van der Lugt, Meike Willemijn Vernooij.   

Abstract

Presence of cerebral microbleeds indicates underlying vascular brain disease and has been implicated in lobar hemorrhages and dementia. However, it remains unknown whether microbleeds also reflect more systemic vascular burden. We investigated the association of microbleeds with all-cause and cardiovascular related mortality in the general population. We rated the brain magnetic resonance imaging scans of 3979 Rotterdam Scan Study participants to determine presence, number, and location of microbleeds. Cox proportional hazards models, adjusted for age, sex, subcohort, vascular risk factors, and other MRI markers of cerebral vascular disease, were applied to quantify the association of microbleeds with mortality. After a mean follow up of 5.2 (±1.1) years, 172 (4.3 %) people had died. Presence of microbleeds, and particularly deep or infratentorial microbleeds, was significantly associated with an increased risk of all-cause mortality [sex-, age-, subcohort adjusted hazard ratio (HR) 2.27; CI 1.50-3.45], independent of vascular risk factors (HR 1.87; 95 % CI 1.20-2.92). The presence of deep or infratentorial microbleeds strongly associated with the risk of cardiovascular related mortality (HR 4.08; CI 1.78-9.39). Mortality risk increased with increasing number of microbleeds. The presence of microbleeds, particularly multiple microbleeds and those in deep or infratentorial regions, indicates an increased risk of mortality, independent of other MRI markers of cerebral vascular disease. Our data suggest that microbleeds may mark severe underlying vascular pathology associated with poorer survival.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24072508     DOI: 10.1007/s10654-013-9854-3

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  28 in total

Review 1.  Cardiovascular disease in the developing world and its cost-effective management.

Authors:  Thomas A Gaziano
Journal:  Circulation       Date:  2005-12-06       Impact factor: 29.690

2.  Apolipoprotein E genotyping by one-stage PCR.

Authors:  P R Wenham; W H Price; G Blandell
Journal:  Lancet       Date:  1991-05-11       Impact factor: 79.321

3.  Cerebral microbleeds are predictive of mortality in the elderly.

Authors:  Irmhild Altmann-Schneider; Stella Trompet; Anton J M de Craen; Adriaan C G M van Es; J Wouter Jukema; David J Stott; Naveed Sattar; Rudi G J Westendorp; Mark A van Buchem; Jeroen van der Grond
Journal:  Stroke       Date:  2011-01-13       Impact factor: 7.914

Review 4.  Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges.

Authors:  Leonardo Pantoni
Journal:  Lancet Neurol       Date:  2010-07       Impact factor: 44.182

5.  Brain tissue volumes in the general elderly population. The Rotterdam Scan Study.

Authors:  M Arfan Ikram; Henri A Vrooman; Meike W Vernooij; Fedde van der Lijn; Albert Hofman; Aad van der Lugt; Wiro J Niessen; Monique M B Breteler
Journal:  Neurobiol Aging       Date:  2007-01-19       Impact factor: 4.673

6.  Cerebral microbleeds: accelerated 3D T2*-weighted GRE MR imaging versus conventional 2D T2*-weighted GRE MR imaging for detection.

Authors:  Meike W Vernooij; M Arfan Ikram; Piotr A Wielopolski; Gabriel P Krestin; Monique M B Breteler; Aad van der Lugt
Journal:  Radiology       Date:  2008-05-19       Impact factor: 11.105

7.  Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds.

Authors:  F Fazekas; R Kleinert; G Roob; G Kleinert; P Kapeller; R Schmidt; H P Hartung
Journal:  AJNR Am J Neuroradiol       Date:  1999-04       Impact factor: 3.825

8.  Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study.

Authors:  M W Vernooij; A van der Lugt; M A Ikram; P A Wielopolski; W J Niessen; A Hofman; G P Krestin; M M B Breteler
Journal:  Neurology       Date:  2008-04-01       Impact factor: 9.910

9.  Kidney function is related to cerebral small vessel disease.

Authors:  M Arfan Ikram; Meike W Vernooij; Albert Hofman; Wiro J Niessen; Aad van der Lugt; Monique M B Breteler
Journal:  Stroke       Date:  2007-11-29       Impact factor: 7.914

10.  Five-year mortality in relation to dementia and cognitive function in 95-year-olds.

Authors:  Anne Börjesson-Hanson; Deborah Gustafson; Ingmar Skoog
Journal:  Neurology       Date:  2007-11-27       Impact factor: 9.910

View more
  21 in total

1.  The Rotterdam Study: 2016 objectives and design update.

Authors:  Albert Hofman; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2015-09-19       Impact factor: 8.082

2.  Cerebral Microbleeds as Predictors of Mortality: The Framingham Heart Study.

Authors:  José R Romero; Sarah R Preis; Alexa Beiser; Jayandra J Himali; Ashkan Shoamanesh; Philip A Wolf; Carlos S Kase; Ramachandran S Vasan; Charles DeCarli; Sudha Seshadri
Journal:  Stroke       Date:  2017-01-31       Impact factor: 7.914

3.  Cerebral microbleeds and risk of incident dementia: the Framingham Heart Study.

Authors:  José R Romero; Alexa Beiser; Jayandra J Himali; Ashkan Shoamanesh; Charles DeCarli; Sudha Seshadri
Journal:  Neurobiol Aging       Date:  2017-03-06       Impact factor: 4.673

4.  Clinical Significance of Magnetic Resonance Imaging Markers of Vascular Brain Injury: A Systematic Review and Meta-analysis.

Authors:  Stéphanie Debette; Sabrina Schilling; Marie-Gabrielle Duperron; Susanna C Larsson; Hugh S Markus
Journal:  JAMA Neurol       Date:  2019-01-01       Impact factor: 18.302

Review 5.  Anticoagulation for Atrial Fibrillation in Patients with Cerebral Microbleeds.

Authors:  Duncan Wilson; H Rolf Jäger; David J Werring
Journal:  Curr Atheroscler Rep       Date:  2015-08       Impact factor: 5.113

6.  Microbleeds in the Secondary Prevention of Small Subcortical Strokes Trial: Stroke, mortality, and treatment interactions.

Authors:  Ashkan Shoamanesh; Lesly A Pearce; Carlos Bazan; Luciana Catanese; Leslie A McClure; Mukul Sharma; Joan Marti-Fabregas; David C Anderson; Carlos S Kase; Robert G Hart; Oscar R Benavente
Journal:  Ann Neurol       Date:  2017-07-19       Impact factor: 10.422

7.  Clinical significance of cerebral microbleeds on MRI: A comprehensive meta-analysis of risk of intracerebral hemorrhage, ischemic stroke, mortality, and dementia in cohort studies (v1).

Authors:  Andreas Charidimou; Sara Shams; Jose R Romero; Jie Ding; Roland Veltkamp; Solveig Horstmann; Gudny Eiriksdottir; Mark A van Buchem; Vilmundur Gudnason; Jayandra J Himali; M Edip Gurol; Anand Viswanathan; Toshio Imaizumi; Meike W Vernooij; Sudha Seshadri; Steven M Greenberg; Oscar R Benavente; Lenore J Launer; Ashkan Shoamanesh
Journal:  Int J Stroke       Date:  2018-01-17       Impact factor: 5.266

8.  Incidence of symptomatic hemorrhage in patients with lobar microbleeds.

Authors:  Ellis S van Etten; Eitan Auriel; Kellen E Haley; Alison M Ayres; Anastasia Vashkevich; Kristin M Schwab; Jonathan Rosand; Anand Viswanathan; Steven M Greenberg; M Edip Gurol
Journal:  Stroke       Date:  2014-06-19       Impact factor: 7.914

Review 9.  The impact of atrial fibrillation and its treatment on dementia.

Authors:  Arun Kanmanthareddy; Ajay Vallakati; Arun Sridhar; Madhu Reddy; Hari Priya Sanjani; Jayasree Pillarisetti; Donita Atkins; Sudharani Bommana; Misty Jaeger; Loren Berenbom; Dhanunjaya Lakkireddy
Journal:  Curr Cardiol Rep       Date:  2014-08       Impact factor: 2.931

10.  Cerebral Microbleeds and the Effect of Intensive Blood Pressure Reduction on Hematoma Expansion and Functional Outcomes: A Secondary Analysis of the ATACH-2 Randomized Clinical Trial.

Authors:  Ashkan Shoamanesh; Andrea Morotti; Javier M Romero; Jamary Oliveira-Filho; Frieder Schlunk; Michael J Jessel; Alison M Ayres; Anastasia Vashkevich; Kristin Schwab; Mohammad R Afzal; Christy Cassarly; Renee H Martin; Adnan I Qureshi; Steven M Greenberg; Jonathan Rosand; Joshua N Goldstein
Journal:  JAMA Neurol       Date:  2018-07-01       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.